The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has ...

Three of the health secretary’s picks to replace fired members of an influential panel that sets U.S. vaccine policies have filed statements in court flagging concerns about vaccines.